Omacetaxine mepesuccinate (Synribo®)

OFFICE / SELF ADMINISTRATION (By Caregiver OR Patient with Proper Training) - SUBCUTANEOUS INJECTION

Indications for Prior Authorization:

Chronic myeloid leukemia

  • Treatment of chronic or accelerated phase chronic myeloid leukemia (CML) in adult patients with resistance and/or intolerance to 2 or more tyrosine kinase inhibitors (TKIs)
  • TKIs with this FDA indication include the following: 
    • Bosutinib (Bosulif®)
    • Dasatinib (Sprycel®)
    • Imatinib (Gleevec®)
    • Nilotinib (Tasigna®)
    • Ponatinib (Iclusiq®)

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Any other diagnosis not listed in the approved indications

All of the following must be met as a condition(s) for coverage:

Chronic or accelerated phase chronic myeloid leukemia (CML)

  • Treatment of chronic or accelerated phase chronic myeloid leukemia (CML) in adult patients AND
  • Patient is resistant and/or intolerant to 2 or more tyrosine kinase inhibitors (TKIs)

The drug is not covered for:

  • Any indication not listed in this policy

Dosing:

Maximum dose

  • There is no well-established maximum dose for the approved indication according to the prescribing information

General dosing consideration

  • Treatment cycles may be delayed and/or the number of days of dosing during the cycle reduced for hematologic toxicities (eg, neutropenia, thrombocytopenia)

Adult

  • Initial dosage: 1.25 mg/m2 subcutaneously twice daily for 14 consecutive days every 28 days, over a 28-day cycle. Repeat cycles every 28 days until patients achieve a hematologic response
  • Maintenance dosage: 1.25 mg/m2 subcutaneously twice daily for 7 consecutive days every 28 days, over a 28-day cycle
  • Dosage adjustment:
    • Hematologic toxicity: If a patient experiences grade 4 neutropenia (absolute neutrophil count [ANC] less than 0.5 × 109/L) or grade 3 thrombocytopenia (platelet counts less than 50 × 109/L) during a cycle, delay starting the next cycle until ANC is 1 × 109/L or higher and platelet count is 50 × 109/L or higher. For the next cycle, reduce the number of dosing days by 2 days (eg, to 12 or 5 days)
    • Nonhematologic toxicity: Manage other clinically significant nonhematologic toxicity symptomatically. Interrupt and/or delay omacetaxine until toxicity is resolved

Missed dose

  • If a dose is missed, skip that dose and resume with the next regularly scheduled dose. Do not administer 2 doses at the same time to make up for a missed dose

Pediatric

  • Safety and effectiveness have not been established

Renal function impairment

  • There is no dosage adjustment provided in the manufacturer's labeling (has not been studied)
  • Based on the minimal amount of unchanged drug excreted in the urine, dosage adjustment is not likely necessary

Hepatic function impairment

  • There is no dosage adjustment provided in the manufacturer's labeling (has not been studied)

Approval:

One year


 

Last review date: July 24, 2016

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar